BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » cynata » Page 4

Cynata Therapeutics Secures $6M in Capital Raise, $10M with Payment from FUJIFILM

January 24, 2017 By Cade Hildreth (CEO) Leave a Comment

Cynata - Capital Raise of $6M

Cynata Successfully Completes Capital Raising

Cynata TherapeuticsMelbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval.  [Read more…]

Filed Under: iPS Cells, MSCs Tagged With: cynata, CYP-001, financing, iPSC

Cynata’s MSC Technology Demonstrates Significant Efficacy in Preclinical Asthma Study

October 20, 2016 By Cade Hildreth (CEO) Leave a Comment

Cynata Asthma Study

• Data suggests Cynata’s unique Cymerus™ iPSC-generated MSCs may have potential clinical use as a treatment for asthma

• Intranasal administration of Cymerus™ MSCs completely normalised airway hyperresponsiveness in a mouse model of asthma [Read more…]

Filed Under: iPS Cells, MSCs Tagged With: asthma, cynata, preclinical

FUJIFILM Expands Its Reign in Regenerative Medicine

September 8, 2016 By Cade Hildreth (CEO) Leave a Comment

FUJIFILM Expands Its Reign in Regenerative Medicine

It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]

Filed Under: iPS Cells, MSCs Tagged With: Axiogenesis, BrainXell, CardioCell, cynata, FUJIFILM

Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet

September 5, 2016 By Cade Hildreth (CEO) Leave a Comment

FUJIFILM Sign Term Sheet

Melbourne, Australia; 5 September 2016 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016. [Read more…]

Filed Under: iPS Cells, MSCs Tagged With: cynata, FUJIFILM

Cynata Files to Begin Phase 1 Trial for CYP-001, World’s First Allogeneic iPSC Product

August 1, 2016 By Cade Hildreth (CEO) Leave a Comment

Cynata Files Application to Commence Phase 1 Clinical Trial for CYP-001, World's First Allogeneic iPSC Product

Cynata TherapeuticsAustralian stem cell company Cynata Therapeutics announced that it has filed an application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I clinical trial for its lead product, CYP-001. CYP-001 is an iPSC-derived mesenchymal stem cell product that is anticipated to be the world’s first allogeneic iPSC product to enter a clinical trial.

To learn more, read the full press release issued by Cynata Therapeutics, printed with permission from Cynata CEO, Dr. Macdonald. [Read more…]

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: clinical trial, Cymerus, cynata, iPSC, MSC

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.